

EXECUTION VERSION

21 September 2022

Enzyvant Therapeutics Holdings Limited (company number 10317630) (the “Company”)

SOLVENCY STATEMENT UNDER SECTION 643 OF THE COMPANIES ACT 2006 (“CA 2006”) MADE ON 21 SEPTEMBER 2022

We, the directors named below (being all of the directors of the Company as at the date of this statement), make the following statement under section 643 of the CA 2006 for the purposes of section 642 of the CA 2006.

Having taken into account all of the Company’s liabilities (including any contingent or prospective liabilities), we have formed the opinion that:


- As regards the Company’s situation as at the date of this statement, there is no ground on which the Company could then be found to be unable to pay (or otherwise discharge) its debts.
- The Company will be able to pay (or otherwise discharge) its debts as they fall due during the year immediately following the date of this statement.

[Signature page follows]




RM 26/09/2022 #130
COMPANIES HOUSE

Signed by:

DocuSigned by:

E140485E3B5647E.....
Director

Name: Mark Craig

Date: 21 September 2022

DocuSigned by:

EE314F301343448.....
Director

Name: Jason Antony Reader

Date: 21 September 2022